GL1X · GenesisL1 explorer

Research workbench

Complex structure of hevb EV93 main protease 3C with rupintrivir (AG7088)

Analyse Complex structure of hevb EV93 main protease 3C with rupintrivir (AG7088) in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3RUO
Type
protein
Length
365 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Hevb EV93 3C protease
EC
3.4.22.28
UniProt
Q5DSM6
Ligands
AG7, MG, CL
Pockets
3 · best druggability 0.32

Structure

x-ray diffraction · 2 distinct chains · 13% helix, 56% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AHevb EV93 3C protease (EC 3.4.22.28)protein18413% helix, 56% strandQ5DSM6
BHevb EV93 3C protease (EC 3.4.22.28)protein18113% helix, 56% strandQ5DSM6

Ligands and binding sites

  • AG7 · 4-{2-(4-fluoro-benzyl)-6-methyl-5-[(5-methyl-isoxazole-3-carbonyl)-amino]-4-oxo-heptanoylamino}-5-(2-oxo-pyrrolidin-3-yl)-pentanoic acid ethyl ester · ligand · 2 copies · chains A, B
  • MG · Magnesium ion · metal · 2 copies · chains A, B
  • CL · Chloride ion · ion · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1810.320.7423empty
2560.310.7516empty
3840.300.7222empty

Interfaces

1 interface between chains.

  • A–B · 751 Ų buried · 10 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 3RUO · Complex structure of HevB EV93 main protease 3C with Rupintrivir (AG7088) · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.